Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07893821). This is a study registration, not published results. Lead sponsor: Pavel Antiperovitch. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 10 participants (ESTIMATED). Conditions: Atrial Fibrillation (Paroxysmal), Hypertension, Heart Failure With Preserved Ejection Fraction (HFPEF). Interventions: PROCEDURE: Catheter-based renal artery electrical stimulation (as a feasibility assessment for renal denervation). Primary outcome measures: Technical Success Rate of Renal Artery Cannulationn , At the time of the procedure; Successful Delivery of Electrical Stimulation , At the time of the procedure; Change in Invasive Arterial Blood Pressure During Renal Artery Stimulation , At the time of procedure. Brief summary: High blood pressure is a major risk factor for atrial fibrillation (AF), an irregular heart rhythm, and heart failure with preserved ejection fraction (HFpEF), a condition in which the heart becomes stiff and cannot relax properly. Both conditions can significantly affect quality of life and frequently occur together. In individuals with high blood pressure, increased activity of the nerves surrounding the kidneys can further elevate blood pressure and contribute to strain on the heart. Renal denervation (RDN) is a procedure designed to lower blood pressure by reducing the activity of these nerves using a thin catheter and controlled energy. RDN has been shown to lower blood pressure safely in many patients; however, the potential benefits in individuals with concurrent AF and HFpEF remain uncertain. This pilot study will be conducted in two phases. Phase 1 will assess the safety and feasibility of accessing the renal arteries and evaluating blood pressure responses to brief electrical stimulation of the renal nerves.